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Benzodiazepine receptor solubilized from bovine cortical membranes was bound to a new benzodiazepine 
affinity column, the synthesis of which is described. Bio-specific elution with the benzodiazepine com- 
pound chlorazepate resulted in the elution of fractions highly enriched in specific binding for the GABA 
receptor agonist muscimol. Specific activity for [3H]muscimol binding was > 1.3 nmol/mg protein. It is 
shown that [3H]flunitrazepam binding activity can be recovered by removal of chlorazepate from the 
purified fraction. These results strongly support a model which suggests that the 2 binding sites reside on 
the same physical entity. 
GABA receptor Benrodiazepine receptor Isolation Affinity chromatography 
1. INTRODUCTION 
A large number of observations on brain mem- 
brane-bound and soluble benzodiazepine (BZ) 
and Na+-independent GABA receptors have led 
to the concept of a GABA-BZ ionophore com- 
plex. This complex is thought to mediate many of 
the sedative, anxiolytic and anticonvulsant actions 
of BZ, barbiturates and related compounds (re- 
view [l]). Evidence for an association of the two 
activities in detergent extracts of brain membranes 
has been obtained 12-51 but it remains to be estab- 
lished that the two activities are indeed located on 
the same physical entity. 
room temperature with 4.2 g iodoacetate in 40 ml 
total vol. at pH 5.0. I-Ethyl-3-(3_dimethylamino- 
propyl)carbodiimide (1 g) was included to catalyze 
the reaction. The gel was washed and reacted over- 
night at room temperature with 144 mg of the BZ 
ligand Ro 7-1986/l in 100 mM Na+-carbonate 
(pH 9.0)/5% ethanol (v/v). The gel was finally 
treated with 0.2% mercaptoethanol to stop the re- 
action and’washed exhaustively. The concentration 
of the bound ligand was estimated from a UV dif- 
ference spectrum of the affinity gel versus a con- 
trol gel (treated identically but with the BZ ligand 
omitted). 
We report here of the use of a BZ affinity col- 
timn which purifies the high-affinity binding sites 
for both the specific GABA receptor agonist, mus- 
cimol. and the BZ ligand flunitrazepam. 
2. MATERIALS AND METHODS 
To synthesize the BZ affinity gel, 20 ml adipic 
dihydrazide agarose (Sigma) was reacted for 3 h at 
Abbreviations: GABA, y-aminobutyric acid; BZ, benzo- 
diazepine; EDTA, ethylene-diamine-N,N,N’,N’-tetra- 
acetic acid; HEPES, 4-(2-hydroxyethyl)-l-piperazine- 
ethanesulfonic acid; SDS-PAGE, sodium dodecylsul- 
phate-polyacrylamide gel electrophoresis 
BZ receptor was solubilized from the bovine 
cortex membranes by a procedure similar to that 
in 131, but the deoxycholate was not exchanged for 
Triton X-100. Protease inhibitors [5] were included 
to protect the receptor and to maximize its recov- 
ery. The soluble BZ receptor was applied to the 
affinity column (2.6 x 4.6 cm) at 60 ml/h. The 
column was washed overnight with 500 ml 50 mM 
NaCl/S mM HEPES (pH 7.5)/0.1 mM EDTA/ 
0.1% (w/v) Triton X-100. It was finally washed 
with 50 ml of 20 mM Na+-phosphate (pH 7.5)/ 
0.1% Triton X-100. The receptor was eluted with 
IO mM Na+-phosphate (pH 7.5)/10 mM chloraze- 
pate/O. 1% Triton X- 100. 
[3H]Flunitrazepam (72 Ci/mmol) and [3H]mus- 
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cimol(9.5 Ci/mmol) were from the Radiochemical 
Centre (Amersham). Both ligand binding activities 
were assayed by a polyethylene glycol precipita- 
tion/filtration method [6]. The receptor was di- 
luted for assay into a medium containing 10 mM 
Na+ -phosphate (pH 7.5)/0.1 mM EDTA/O. 1% 
Triton X- 100. 
SDS-PAGE was performed as in [7] with a 10% 
acrylamide gel. The purified protein was precipi- 
tated with 12% trichloroacetic acid prior to elec- 
trophoresis. 
3. RESULTS AND DISCUSSION 
Fig.1 shows the chemical structure of the BZ af- 
finity column used in this work. The BZ ligand 
preserves a positive charge in the covalently bound 
form on the alkylated amino-group. The final con- 
centration of immobilized BZ ligand on the gel 
was 0.3-0.5 pmol/ml gel (3 prep.). Application of 
an affinity column with a similar spacer arm, but 
with the BZ delorazepam, has been reported [8]. 
When the deoxycholate-solubilized receptor 
from bovine brain cortex was applied to the af- 
finity column, > 87% of the specific [jH]flunitraze- 
pam binding sites were retained by the column; 
< 5% of the bound BZ binding sites were lost dur- 
ing the subsequent extensive washing of the col- 
umn. Bio-specific elution was achieved by the 
water-soluble BZ ligand, chlorazepate. The result- 






Fig. I. Structure of the immobilized benzodiazepine 
affinity gel used. 
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Fig.2. (A) Binding of ]3H]muscimol to the purified frac- 
tion. The receptor was incubated with [3H]muscimol for 
30 min at 0°C. Non-specific binding was measured in 
the presence of a IOOO-fold excess of unlabelled mus- 
cimol: (0) specific binding; (0) non-specific binding. (B) 
Scatchard plot of the [JH]muscimol binding to the 
purified component. 
ing fractions could not be assayed directly for [3H]- 
flunitrazepam binding activity due to the presence 
of a high concentration of chlorazepate. However, 
these fractions were found to be highly enriched in 
specific [3H]muscimol binding sites. The yield of 
[3H]muscimol binding activity was 14-20s of the 
applied soluble extract. This corresponded to 
600 pmol[3H]muscimol binding sites (measured at 
saturation) in 30 ml total vol. The protein deter- 
mination was difficult due to both the low concen- 
tration of protein and the presence of chlorazepate 
which interfered with the protein assay 191. [)H]- 
Muscimol binding was saturable (fig.2A). Non- 
specific binding was very low (< 3% of the total 
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Fig.3. Scan of a SDS-polyacrylamide gel (10%) of the 
purified complex recovered from the DEAE-cellulose 
column stained with Coomassie blue; TD, position of 
the tracking dye. 
binding at 100 nM). A Scatchard plot of the sat- 
uration curve (fig.2B) showed the presence of a 
single class of [3H]muscimoi binding sites. The 
Kd-values found in 3 different preparations were 
from 16-25 nM. 
SDS-PAGE was performed and the gels stained 
by the Coomassie blue or a silver [lo] method. By 
comparison with protein standards, it was con- 
firmed in both staining methods that the protein 
content of the [3H]muscimol binding fractions was 
very low (< 15 pg/ml). The specific binding ac- 
tivity can therefore be estimated to be > 1300 
pmol/mg protein. Both staining methods showed a 
single major band in the region of M, 53 000. A 
scan of a typical preparation of the purified recep- 
tor is shown in fig. 3. 
Thus we have isolated saturable [3H]muscimol 
binding activity with a BZ affinity column by 
means of bio-specific elution with a BZ ligand. 
This observation provides strong evidence for a 
tight association of GABA and BZ binding sites 
that can be preserved during isolation. That such 
an association in one protein or molecular complex 
is characteristic of a native structure from the orig- 
inal membrane is indicated by the finding that the 
2 binding sites possess an identical target size in 
the brain membranes [5,11]. 
There have been two reports on the use of BZ 
affinity columns for the purification of the BZ re- 
ceptor [2,8]. However, in [2], bio-specific elution 
and high specitic activity, as reported here, have 
not been obtained; in the other case [81, co- 
purification of a GABA binding site was not shown. 
The ratio of the 2 classes of binding site was 
examined after the removal of chlorazepate. This 
was approached by binding the receptor to either a 
hydroxyapatite or a DEAE-cellulose column, fol- 
lowed by washing of the column and elution of the 
protein with 0.8 M Na+-phosphate and 0.6 M 
KCl, respectively. With both methods specific 
flunitrazepam binding is recovered in the purified 
material. Specific [3H]muscimol and [jH]fluni- 
trazepam binding were measured close to satura- 
tion; i.e., at 30 nM and 25 nM, respectively. The 
ratio of [JH]muscimol binding to that of [jH]fluni- 
trazepam was 3.2 for the material resulting from 
the hydroxyapatite column and (5 expt.) for that 
recovered from the ion-exchange column 2.9-3.5. 
However, these results should be viewed with cau- 
tion at this preliminary stage: this is due to possi- 
ble residual contamination by chlorazepate, to 
possible losses of the specifically bound ligand (es- 
pecially [3H]muscimol) during the filter washing in 
the assay, and to the possibility of differential inac- 
tivation of the 2 binding sites during the pro- 
cedures involved. For these reasons, the exact ratio 
of the 2 binding sites on the purified complex re- 
mains to be established. 
Recent experiments have shown that chloraze- 
pate can indeed be removed completely from the 
present preparation. Results on the subunit and 
oligomeric structure and the pharmacological 
properties of this purified BZ-GABA receptor 
complex will be presented in full elsewhere. 
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